Indication
Aggressive Systemic Mastocytosis
4 clinical trials
3 products
Product
midostaurinClinical trial
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid MalignanciesStatus: Completed, Estimated PCD: 2022-10-05
Product
AvapritinibProduct
bezuclastinibClinical trial
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic MastocytosisStatus: Active (not recruiting), Estimated PCD: 2026-01-31
Clinical trial
A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic MastocytosisStatus: Recruiting, Estimated PCD: 2025-01-01